Shares of COMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) have received an average rating of "Buy" from the six analysts that are covering the company, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have covered the stock in the last year is $30.60.
CMPS has been the subject of several recent research reports. Maxim Group reduced their price objective on COMPASS Pathways from $22.00 to $12.00 and set a "buy" rating for the company in a research note on Friday, November 1st. Royal Bank of Canada restated an "outperform" rating and set a $18.00 price target on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Finally, HC Wainwright lowered their price target on shares of COMPASS Pathways from $60.00 to $45.00 and set a "buy" rating on the stock in a research report on Thursday.
Check Out Our Latest Stock Report on COMPASS Pathways
COMPASS Pathways Price Performance
CMPS stock traded up $0.15 during trading on Friday, hitting $4.57. The stock had a trading volume of 1,307,053 shares, compared to its average volume of 1,310,584. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways has a twelve month low of $3.16 and a twelve month high of $12.75. The stock has a market capitalization of $312.68 million, a P/E ratio of -2.08 and a beta of 2.28. The company's 50-day moving average price is $4.10 and its two-hundred day moving average price is $5.49.
Hedge Funds Weigh In On COMPASS Pathways
Several institutional investors have recently bought and sold shares of CMPS. Hennion & Walsh Asset Management Inc. grew its position in COMPASS Pathways by 34.7% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 148,134 shares of the company's stock valued at $933,000 after acquiring an additional 38,145 shares in the last quarter. Rosalind Advisors Inc. lifted its holdings in COMPASS Pathways by 6.5% during the 3rd quarter. Rosalind Advisors Inc. now owns 781,423 shares of the company's stock worth $4,923,000 after buying an additional 47,423 shares in the last quarter. Propel Bio Management LLC acquired a new stake in COMPASS Pathways during the 3rd quarter worth approximately $504,000. Acuta Capital Partners LLC acquired a new stake in COMPASS Pathways in the third quarter valued at approximately $2,435,000. Finally, Walleye Capital LLC acquired a new stake in COMPASS Pathways in the third quarter valued at approximately $2,126,000. 46.19% of the stock is owned by institutional investors and hedge funds.
About COMPASS Pathways
(
Get Free ReportCOMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
Read More
Before you consider COMPASS Pathways, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and COMPASS Pathways wasn't on the list.
While COMPASS Pathways currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
